pre-IPO PHARMA

COMPANY OVERVIEW

Vedanta Biosciences is pioneering a novel class of therapies designed to modulate pathways of interaction between the human microbiome and the host immune system. The first to rationally design a drug candidate based on consortia of human commensal bacteria, Vedanta has capabilities that enable discovery, development, and manufacturing of drugs based on live commensal microbes.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Immunology
  • Infectious Disease
  • Inflammatory Disease
  • Oncology

  • WEBSITE

    https://www.vedantabio.com/


    CAREER WEBSITE

    https://www.vedantabio.com/careers


    SOCIAL MEDIA


    INVESTORS

    bill-melinda-gates-foundation bms fc-capital health-for-life-capital invesco-asset-management jsr-corporation partners-investment puretech-health quad-investment-management rock-springs-capital shinhan-capital-yeollim-partners shinhan-investment-private -equity shumway-capital sv-investment symbiosis


    PRESS RELEASES


    May 9, 2023

    PureTech Founded Entity Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week


    May 9, 2023

    Vedanta Biosciences to Participate in the JMP Securities Life Sciences Conference


    May 8, 2023

    Vedanta Biosciences Receives Fast Track Designation for VE303 and Presents Phase 2 Data at Digestive Disease Week


    Apr 25, 2023

    Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies


    Apr 25, 2023

    PureTech Founded Entity Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies


    For More Press Releases


    Google Analytics Alternative